TDMS Study 05102-06 Pathology Tables
INCIDENCE RATES OF NEOPLASMS BY ANATOMIC SITE (SYSTEMIC LESIONS ABRIDGED) (a)
BENZETHONIUM CHLORIDE
NTP Experiment-Test: 05102-06 Report: PEIRPT05
Study Type: CHRONIC Date: 05/19/95
Route: DERMAL,SOLUTION Time: 18:39:19
Facility: Battelle Columbus Laboratory
Chemical CAS #: 121-54-0
Lock Date: 01/22/92
Cage Range: All
Reasons For Removal: All
Removal Date Range: All
Treatment Groups: Include All
a Number of animals examined microscopically at site and number of animals with lesion
Page 1
NTP Experiment-Test: 05102-06 INCIDENCE RATES OF NEOPLASMS BY ANATOMIC SITE (SYSTEMIC LESIONS ABRIDGED) (a) Report: PEIRPT05
Study Type: CHRONIC BENZETHONIUM CHLORIDE Date: 05/19/95
Route: DERMAL,SOLUTION Time: 18:39:19
____________________________________________________________________________________________________________________________________
B6C3F1 MICE FEMALE 0MG/KG .15MG/KG 0.5MG/KG 1.5MG/KG
____________________________________________________________________________________________________________________________________
DISPOSITION SUMMARY
Animals Initially in Study 60 60 60 60
Scheduled Sacrifice 8 7 10 6
Early Deaths
Moribund Sacrifice 10 4 8 13
Natural Death 3 15 9 7
Accidently Killed 1
Survivors
Terminal Sacrifice 38 34 31 34
Other 2
Animals Examined Microscopically 60 60 58 60
____________________________________________________________________________________________________________________________________
ALIMENTARY SYSTEM
Gallbladder (60) (59)
Histiocytic Sarcoma 1 (2%)
Intestine Large, Rectum (60) (59)
Liposarcoma, Metastatic, Skeletal Muscle 1 (2%)
Intestine Large, Cecum (60) (59)
Intestine Small, Jejunum (60) (58)
Carcinoma 1 (2%)
Hemangiosarcoma 1 (2%)
Liver (60) (60)
Hemangioma 1 (2%)
Hemangiosarcoma 1 (2%)
Hemangiosarcoma, Metastatic, Spleen 1 (2%)
Hepatocellular Carcinoma 7 (12%) 10 (17%)
Hepatocellular Carcinoma, Multiple 5 (8%) 1 (2%)
Hepatocellular Adenoma 10 (17%) 13 (22%)
Hepatocellular Adenoma, Multiple 11 (18%) 6 (10%)
Hepatocholangiocarcinoma, Multiple 1 (2%)
Histiocytic Sarcoma 3 (5%)
Plasma Cell Tumor Malignant, Metastatic,
Spleen 1 (2%)
Mesentery (10) (9)
Hemangioma 1 (10%)
Hepatocholangiocarcinoma, Metastatic, Liver 1 (11%)
Histiocytic Sarcoma 1 (10%)
Myxosarcoma, Metastatic, Skin 1 (10%)
Pancreas (60) (59)
Histiocytic Sarcoma 1 (2%)
Leiomyosarcoma, Metastatic, Uterus 1 (2%)
Salivary Glands (60) (60)
Page 2
NTP Experiment-Test: 05102-06 INCIDENCE RATES OF NEOPLASMS BY ANATOMIC SITE (SYSTEMIC LESIONS ABRIDGED) (a) Report: PEIRPT05
Study Type: CHRONIC BENZETHONIUM CHLORIDE Date: 05/19/95
Route: DERMAL,SOLUTION Time: 18:39:19
____________________________________________________________________________________________________________________________________
B6C3F1 MICE FEMALE 0MG/KG .15MG/KG 0.5MG/KG 1.5MG/KG
____________________________________________________________________________________________________________________________________
ALIMENTARY SYSTEM - cont
Stomach, Forestomach (59) (59)
____________________________________________________________________________________________________________________________________
CARDIOVASCULAR SYSTEM
Heart (60) (60)
Plasma Cell Tumor Malignant, Metastatic,
Spleen 1 (2%)
____________________________________________________________________________________________________________________________________
ENDOCRINE SYSTEM
Adrenal Cortex (60) (60)
Histiocytic Sarcoma 1 (2%)
Pituitary Gland (60) (55)
Histiocytic Sarcoma 1 (2%)
Pars Distalis, Adenoma 6 (10%) 5 (9%)
Thyroid Gland (60) (60)
Follicular Cell, Adenoma 3 (5%) 1 (2%)
Follicular Cell, Carcinoma 1 (2%)
____________________________________________________________________________________________________________________________________
GENERAL BODY SYSTEM
None
____________________________________________________________________________________________________________________________________
GENITAL SYSTEM
Ovary (60) (58)
Cystadenoma 3 (5%) 2 (3%)
Hemangioma 1 (2%)
Histiocytic Sarcoma 2 (3%)
Uterus (60) (59)
Carcinoma 1 (2%)
Histiocytic Sarcoma 3 (5%) 1 (2%)
Leiomyosarcoma 1 (2%)
Polyp Stromal 1 (2%) 1 (2%)
____________________________________________________________________________________________________________________________________
HEMATOPOIETIC SYSTEM
Blood (1)
Bone Marrow (60) (59)
Hemangiosarcoma, Metastatic, Spleen 3 (5%)
Histiocytic Sarcoma 2 (3%)
Plasma Cell Tumor Malignant, Metastatic,
Page 3
NTP Experiment-Test: 05102-06 INCIDENCE RATES OF NEOPLASMS BY ANATOMIC SITE (SYSTEMIC LESIONS ABRIDGED) (a) Report: PEIRPT05
Study Type: CHRONIC BENZETHONIUM CHLORIDE Date: 05/19/95
Route: DERMAL,SOLUTION Time: 18:39:19
____________________________________________________________________________________________________________________________________
B6C3F1 MICE FEMALE 0MG/KG .15MG/KG 0.5MG/KG 1.5MG/KG
____________________________________________________________________________________________________________________________________
HEMATOPOIETIC SYSTEM - cont
Spleen 1 (2%)
Lymph Node (7) (3)
Lumbar, Histiocytic Sarcoma 1 (14%)
Mediastinal, Histiocytic Sarcoma 1 (14%)
Pancreatic, Hepatocholangiocarcinoma,
Metastatic, Liver 1 (33%)
Lymph Node, Mandibular (60) (60)
Hemangioma 1 (2%)
Histiocytic Sarcoma 3 (5%)
Plasma Cell Tumor Malignant, Metastatic,
Spleen 1 (2%)
Lymph Node, Mesenteric (57) (54)
Histiocytic Sarcoma 3 (5%)
Plasma Cell Tumor Malignant, Metastatic,
Spleen 1 (2%)
Spleen (60) (59)
Hemangiosarcoma 1 (2%) 3 (5%)
Histiocytic Sarcoma 1 (2%)
Plasma Cell Tumor Malignant 1 (2%)
Thymus (49) (51)
Plasma Cell Tumor Malignant, Metastatic,
Spleen 1 (2%)
____________________________________________________________________________________________________________________________________
INTEGUMENTARY SYSTEM
Skin (60) (59) (58) (59)
Subcutaneous Tissue, Fibrosarcoma 2 (3%)
Subcutaneous Tissue, Hemangiosarcoma 1 (2%)
Subcutaneous Tissue, Sarcoma 1 (2%)
Skin, Inguinal (2) (1) (1)
Skin, Site of Application-No Mass (5) (10) (9) (27)
Subcutaneous Tissue, Hemangioma 1 (20%)
Skin, Site of Application-Mass (1) (1)
Subcutaneous Tissue, Myxosarcoma, Multiple 1 (100%)
Subcutaneous Tissue, Sarcoma 1 (100%)
____________________________________________________________________________________________________________________________________
MUSCULOSKELETAL SYSTEM
Bone (60) (59)
Liposarcoma, Metastatic, Skeletal Muscle 1 (2%)
Skeletal Muscle (4)
Hemangiosarcoma, Metastatic, Spleen 1 (25%)
Leiomyosarcoma, Metastatic, Uterus 1 (25%)
Liposarcoma 1 (25%)
____________________________________________________________________________________________________________________________________
Page 4
NTP Experiment-Test: 05102-06 INCIDENCE RATES OF NEOPLASMS BY ANATOMIC SITE (SYSTEMIC LESIONS ABRIDGED) (a) Report: PEIRPT05
Study Type: CHRONIC BENZETHONIUM CHLORIDE Date: 05/19/95
Route: DERMAL,SOLUTION Time: 18:39:19
____________________________________________________________________________________________________________________________________
B6C3F1 MICE FEMALE 0MG/KG .15MG/KG 0.5MG/KG 1.5MG/KG
____________________________________________________________________________________________________________________________________
NERVOUS SYSTEM
Spinal Cord (2)
Hemangiosarcoma, Metastatic, Spleen 1 (50%)
____________________________________________________________________________________________________________________________________
RESPIRATORY SYSTEM
Lung (60) (60)
Alveolar/Bronchiolar Adenoma 1 (2%) 2 (3%)
Alveolar/Bronchiolar Carcinoma 1 (2%) 1 (2%)
Carcinoma, Metastatic, Harderian Gland 1 (2%)
Hepatocellular Carcinoma, Metastatic, Liver 5 (8%) 3 (5%)
Hepatocholangiocarcinoma, Metastatic, Liver 1 (2%)
Histiocytic Sarcoma 2 (3%)
Liposarcoma, Metastatic, Skeletal Muscle 1 (2%)
Plasma Cell Tumor Malignant, Metastatic,
Spleen 1 (2%)
____________________________________________________________________________________________________________________________________
SPECIAL SENSES SYSTEM
Harderian Gland (44) (35)
Adenoma 2 (5%) 2 (6%)
Carcinoma 2 (5%) 1 (3%)
Zymbal's Gland (1)
Carcinoma 1 (100%)
____________________________________________________________________________________________________________________________________
URINARY SYSTEM
Kidney (60) (60)
Histiocytic Sarcoma 3 (5%)
Plasma Cell Tumor Malignant, Metastatic,
Spleen 1 (2%)
Urinary Bladder (58) (59)
____________________________________________________________________________________________________________________________________
SYSTEMIC LESIONS
Multiple Organs *(60) *(60) *(58) *(60)
Histiocytic Sarcoma 3 (5%) 1 (2%)
Leukemia Lymphocytic 1 (2%)
Lymphoma Malignant Lymphocytic 1 (2%) 1 (2%) 2 (3%)
Lymphoma Malignant Mixed 5 (8%) 3 (5%)
Lymphoma Malignant Undifferentiated Cell 1 (2%)
____________________________________________________________________________________________________________________________________
* Number of animals with any tissue examined microscopically
Page 5
NTP Experiment-Test: 05102-06 INCIDENCE RATES OF NEOPLASMS BY ANATOMIC SITE (SYSTEMIC LESIONS ABRIDGED) (a) Report: PEIRPT05
Study Type: CHRONIC BENZETHONIUM CHLORIDE Date: 05/19/95
Route: DERMAL,SOLUTION Time: 18:39:19
____________________________________________________________________________________________________________________________________
B6C3F1 MICE FEMALE 0MG/KG .15MG/KG 0.5MG/KG 1.5MG/KG
____________________________________________________________________________________________________________________________________
TUMOR SUMMARY
Total Animals with Primary Neoplasms (b) 42 1 1 43
Total Primary Neoplasms 75 1 1 63
Total Animals with Benign Neoplasms 29 29
Total Benign Neoplasms 40 34
Total Animals with Malignant Neoplasms 27 1 1 27
Total Malignant Neoplasms 35 1 1 29
Total Animals with Metastatic Neoplasms 9 8
Total Metastatic Neoplasm 16 16
Total Animals with Malignant Neoplasms
Uncertain Primary Site
Total Animals with Neoplasms Uncertain-
Benign or Malignant
Total Uncertain Neoplasms
____________________________________________________________________________________________________________________________________
a Number of animals examined microscopically at site and number of animals with lesion
b Primary tumors: all tumors except metastatic tumors
Page 6
NTP Experiment-Test: 05102-06 INCIDENCE RATES OF NEOPLASMS BY ANATOMIC SITE (SYSTEMIC LESIONS ABRIDGED) (a) Report: PEIRPT05
Study Type: CHRONIC BENZETHONIUM CHLORIDE Date: 05/19/95
Route: DERMAL,SOLUTION Time: 18:39:19
____________________________________________________________________________________________________________________________________
B6C3F1 MICE MALE 0MG/KG .15MG/KG 0.5MG/KG 1.5MG/KG
____________________________________________________________________________________________________________________________________
DISPOSITION SUMMARY
Animals Initially in Study 60 60 60 60
Scheduled Sacrifice 10 9 9 10
Early Deaths
Moribund Sacrifice 3 8 4 9
Natural Death 4 4 4 2
Survivors
Terminal Sacrifice 43 38 42 39
Other 1 1
Animals Examined Microscopically 60 59 59 60
____________________________________________________________________________________________________________________________________
ALIMENTARY SYSTEM
Intestine Large, Cecum (60) (60)
Leiomyosarcoma 1 (2%)
Intestine Small, Duodenum (60) (60)
Adenoma 1 (2%)
Intestine Small, Jejunum (60) (60)
Liver (60) (60)
Hemangioma 1 (2%)
Hemangiosarcoma 2 (3%)
Hemangiosarcoma, Multiple 1 (2%) 2 (3%)
Hemangiosarcoma, Metastatic, Skin 1 (2%)
Hemangiosarcoma, Metastatic, Spleen 1 (2%)
Hepatoblastoma 1 (2%)
Hepatocellular Carcinoma 10 (17%) 14 (23%)
Hepatocellular Carcinoma, Multiple 2 (3%) 2 (3%)
Hepatocellular Adenoma 15 (25%) 16 (27%)
Hepatocellular Adenoma, Multiple 13 (22%) 13 (22%)
Histiocytic Sarcoma 1 (2%)
Mesentery (5) (5)
Hemangioma 1 (20%) 1 (20%)
Histiocytic Sarcoma 1 (20%)
Stomach, Glandular (60) (60)
Carcinoid Tumor Malignant 1 (2%)
____________________________________________________________________________________________________________________________________
CARDIOVASCULAR SYSTEM
Heart (60) (60)
Hemangiosarcoma, Metastatic, Liver 1 (2%) 1 (2%)
____________________________________________________________________________________________________________________________________
Page 7
NTP Experiment-Test: 05102-06 INCIDENCE RATES OF NEOPLASMS BY ANATOMIC SITE (SYSTEMIC LESIONS ABRIDGED) (a) Report: PEIRPT05
Study Type: CHRONIC BENZETHONIUM CHLORIDE Date: 05/19/95
Route: DERMAL,SOLUTION Time: 18:39:19
____________________________________________________________________________________________________________________________________
B6C3F1 MICE MALE 0MG/KG .15MG/KG 0.5MG/KG 1.5MG/KG
____________________________________________________________________________________________________________________________________
ENDOCRINE SYSTEM
Adrenal Cortex (60) (60)
Histiocytic Sarcoma 1 (2%)
Adrenal Medulla (60) (60)
Pheochromocytoma Benign 1 (2%)
Islets, Pancreatic (59) (60)
Adenoma 2 (3%) 1 (2%)
Pituitary Gland (58) (58)
Histiocytic Sarcoma 1 (2%)
Thyroid Gland (60) (60)
Hemangiosarcoma, Metastatic, Spleen 1 (2%)
Follicular Cell, Adenoma 1 (2%)
Follicular Cell, Carcinoma 1 (2%) 1 (2%)
____________________________________________________________________________________________________________________________________
GENERAL BODY SYSTEM
None
____________________________________________________________________________________________________________________________________
GENITAL SYSTEM
Epididymis (60) (59)
Histiocytic Sarcoma 1 (2%)
Testes (60) (60)
Interstitial Cell, Adenoma 1 (2%) 1 (2%)
____________________________________________________________________________________________________________________________________
HEMATOPOIETIC SYSTEM
Bone Marrow (60) (60)
Hemangiosarcoma, Metastatic, Liver 1 (2%)
Hemangiosarcoma, Metastatic, Skin 1 (2%)
Hemangiosarcoma, Metastatic, Spleen 1 (2%)
Histiocytic Sarcoma 1 (2%)
Lymph Node (3) (2)
Lymph Node, Mandibular (59) (58)
Lymph Node, Mesenteric (57) (57)
Spleen (60) (60)
Hemangiosarcoma 3 (5%)
Hemangiosarcoma, Metastatic, Liver 1 (2%)
Histiocytic Sarcoma 1 (2%)
Thymus (41) (49)
____________________________________________________________________________________________________________________________________
Page 8
NTP Experiment-Test: 05102-06 INCIDENCE RATES OF NEOPLASMS BY ANATOMIC SITE (SYSTEMIC LESIONS ABRIDGED) (a) Report: PEIRPT05
Study Type: CHRONIC BENZETHONIUM CHLORIDE Date: 05/19/95
Route: DERMAL,SOLUTION Time: 18:39:19
____________________________________________________________________________________________________________________________________
B6C3F1 MICE MALE 0MG/KG .15MG/KG 0.5MG/KG 1.5MG/KG
____________________________________________________________________________________________________________________________________
INTEGUMENTARY SYSTEM
Skin (60) (59) (59) (60)
Melanoma Benign 1 (2%)
Subcutaneous Tissue, Hemangioma 1 (2%)
Subcutaneous Tissue, Hemangiosarcoma 1 (2%) 1 (2%)
Subcutaneous Tissue, Hemangiosarcoma,
Metastatic, Spleen 1 (2%)
____________________________________________________________________________________________________________________________________
MUSCULOSKELETAL SYSTEM
None
____________________________________________________________________________________________________________________________________
NERVOUS SYSTEM
Brain (60) (60)
Histiocytic Sarcoma 1 (2%)
____________________________________________________________________________________________________________________________________
RESPIRATORY SYSTEM
Lung (60) (60)
Alveolar/Bronchiolar Adenoma 11 (18%) 7 (12%)
Alveolar/Bronchiolar Adenoma, Multiple 2 (3%) 1 (2%)
Alveolar/Bronchiolar Carcinoma 1 (2%)
Alveolar/Bronchiolar Carcinoma, Multiple 2 (3%)
Carcinoma, Metastatic, Harderian Gland 1 (2%)
Carcinoma, Metastatic, Thyroid Gland 1 (2%)
Hepatocellular Carcinoma, Metastatic, Liver 2 (3%) 5 (8%)
Histiocytic Sarcoma 1 (2%)
Nose (60) (60)
Glands, Carcinoma 1 (2%)
____________________________________________________________________________________________________________________________________
SPECIAL SENSES SYSTEM
Ear (1) (2)
Fibrosarcoma 1 (100%) 1 (50%)
Harderian Gland (43) (38)
Adenoma 2 (5%) 3 (8%)
Carcinoma 1 (2%)
____________________________________________________________________________________________________________________________________
Page 9
NTP Experiment-Test: 05102-06 INCIDENCE RATES OF NEOPLASMS BY ANATOMIC SITE (SYSTEMIC LESIONS ABRIDGED) (a) Report: PEIRPT05
Study Type: CHRONIC BENZETHONIUM CHLORIDE Date: 05/19/95
Route: DERMAL,SOLUTION Time: 18:39:19
____________________________________________________________________________________________________________________________________
B6C3F1 MICE MALE 0MG/KG .15MG/KG 0.5MG/KG 1.5MG/KG
____________________________________________________________________________________________________________________________________
URINARY SYSTEM
Kidney (60) (60)
Histiocytic Sarcoma 1 (2%)
____________________________________________________________________________________________________________________________________
SYSTEMIC LESIONS
Multiple Organs *(60) *(59) *(59) *(60)
Histiocytic Sarcoma 1 (2%)
Lymphoma Malignant Lymphocytic 1 (2%)
Lymphoma Malignant Mixed 1 (2%) 3 (5%)
Lymphoma Malignant Undifferentiated Cell 1 (2%)
____________________________________________________________________________________________________________________________________
* Number of animals with any tissue examined microscopically
Page 10
NTP Experiment-Test: 05102-06 INCIDENCE RATES OF NEOPLASMS BY ANATOMIC SITE (SYSTEMIC LESIONS ABRIDGED) (a) Report: PEIRPT05
Study Type: CHRONIC BENZETHONIUM CHLORIDE Date: 05/19/95
Route: DERMAL,SOLUTION Time: 18:39:19
____________________________________________________________________________________________________________________________________
B6C3F1 MICE MALE 0MG/KG .15MG/KG 0.5MG/KG 1.5MG/KG
____________________________________________________________________________________________________________________________________
TUMOR SUMMARY
Total Animals with Primary Neoplasms (b) 48 44
Total Primary Neoplasms 72 81
Total Animals with Benign Neoplasms 39 34
Total Benign Neoplasms 49 47
Total Animals with Malignant Neoplasms 18 24
Total Malignant Neoplasms 23 34
Total Animals with Metastatic Neoplasms 4 8
Total Metastatic Neoplasm 8 11
Total Animals with Malignant Neoplasms
Uncertain Primary Site
Total Animals with Neoplasms Uncertain-
Benign or Malignant
Total Uncertain Neoplasms
____________________________________________________________________________________________________________________________________
a Number of animals examined microscopically at site and number of animals with lesion
b Primary tumors: all tumors except metastatic tumors
Page 11
------------------------------------------------------------
---------- END OF REPORT ----------
------------------------------------------------------------